
... BIBLIOGRAPHY ...

- Anderson ML. *Helicobacter pylori* infection. *Postgrad Med* 1994;96:40-49.
- Bayerdorffer E, Miehle S, Mannes GA. Double-blind trial of omeprazole and amoxicillin to cure *Helicobacter pylori* infection in patients with duodenal ulcers. *Gastroenterology* 1995;108:1412-1417.
- Bell GD, Powell KU, Burrige SM, et al. Rapid eradication of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1995;9:41-46.
- Bell GD. Anti-*Helicobacter pylori* therapy: Clearance, elimination, or eradication? *Lancet* 1991;337:310-311.
- Berardi RR. Peptic ulcer disease and Zollinger-Ellison Syndrome. In: DiPiro JT, Talbert RL, Yee GC et al eds. *Pharmacotherapy: A Pathophysiologic Approach*. 3rd edition, Stamford, Conn: Appleton and Lange; 1997.
- Borody TJ, Andrews P, Fracchia G, et al. Omeprazole enhances efficacy of triple therapy in eradicating *Helicobacter pylori*. *Gut* 1995;37:477-481.
- Bozymski EM, Isaacs KL. Special diagnostic and therapeutic considerations in elderly patients with upper gastrointestinal disease. *J Clin Gastroenterol* 1991;13: S65-S75.
- Campbell DR, Kim J, Rose P, et al. The safety of triple therapy with lansoprazole, clarithromycin, and amoxicillin in the eradication of *Helicobacter pylori* (abstr). *Gastroenterology* 1997;112:A82.
- Cave DR. How is *Helicobacter pylori* transmitted? *Gastroenterology* 1997;113(Suppl):S9-S14.
- Ching CK, Leung KP, Yung RWH, et al. Prevalence of metronidazole resistant *Helicobacter pylori* strains among Chinese peptic ulcer patients and normal controls in Hong Kong. *Gut* 1996;38:675-678.
- Clinch D, Banerjee AK, Ostik G. Absence of abdominal pain in elderly patients with peptic ulcer. *Age and Aging* 1984;13:120-123.
- Cryer B, Faust T, Goldschmiedt M, et al. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer diseases: Relationship with demographics, environmental, and histologic factors, including *Helicobacter pylori*. *Am J Gastroenterol* 1992; 87:1747-1754.
- Cutler AF, Schubert T. Long-term *Helicobacter pylori* recurrence after successful eradication with triple therapy. *Am J Gastroenterol* 1993;88:1359-1361.
- Cutler AF, Schubert T. Patient factors affecting *Helicobacter pylori* eradication with triple therapy. *Am J Gastroenterol* 1993;88:505-509.
- de Boer W, Drissen W, Janz A, Tytgat G. Concomitant acid suppression increases the efficacy of traditional anti-*Helicobacter pylori* therapy. *Lancet* 1995;345:817-820.
- deBoer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression of efficacy of treatment for *Helicobacter pylori* infection. *Lancet* 1995;345:817-820.
- Dunn BE. Pathogenic mechanisms of *Helicobacter pylori*. *Gastroenterol Clin North Am* 1993;22:43-57.
- Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. *Arch Intern Med* 1990;150:1881-1884.
- Elashoff J, Grossman M. Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970-1978. *Gastroenterology* 1980;78:280-285.
- EUROGAST Study Group. Epidemiology and risk factors for *Helicobacter pylori* infection among 3194 asymptomatic subjects in 17 populations. *Gut* 1993;34:1672-1676.
- Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. *Ann Int Med* 1995;123:260-268.
- Fendrick AM, Chernow ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. *Ann Intern Med* 1995;123:260-268.
- Fennerty M, Bianchi T, Rose P, Pilmer B, Kidd S, Siepman N. Triple therapy with lansoprazole, clarithromycin, and amoxicillin is highly effective in the eradication of *Helicobacter pylori* infection (abstr). *Gastroenterology* 1997; 112:A116.
- Fennerty M, Lieberman D, Magaret N, and GORGE Consortium. Effectiveness of *H pylori* treatment regimens in clinical practice: A community-based outcomes study (abstr). *Gastroenterology* 1997;112:A14.
- Fennerty MB, Melnyk CS. *Helicobacter pylori*: Review of triple, dual, 7-day, and other treatment strategies. *Formulary* 1995;30:682-688.
- Fennerty MB. Should we abandon metronidazole containing *Helicobacter pylori* treatment regimens? The clinical relevance of metronidazole resistance. *Am J Gastroenterol* 1998;93:2-3.
- Fennerty MB. What are the treatment goals for *Helicobacter pylori*? *Gastroenterology* 1997;113(suppl):S120-S125.

- Fiedorek SC, Malaty HM, Evans DL et al. Factors influencing the epidemiology of *Helicobacter pylori* infection in children. *Pediatrics* 1991;88:578-582.
- Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with *Helicobacter pylori* eradication: seven-year follow-up. *Lancet* 1994;343:258-260.
- Freston J. H2-receptor antagonists and duodenal ulcer recurrence: Analysis of efficacy and commentary on safety, costs, and patient selection. *Am J Gastroenterology* 1987;82:1242.
- Freston M, Freston J. Peptic ulcers in the elderly: Unique features and management. *Geriatrics* 1990;45:39-45.
- Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: Frequency and risk factor models. *Am J Med* 1991;114:735-740.
- Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal drugs: A meta-analysis. *Ann Int Med* 1991;115:787-796.
- Garnett WR, Garabedian-Ruffalo SM. Identification, diagnosis and treatment of acid-related diseases in the elderly: Implications for long-term care. *Pharmacotherapy* 1997;17:938-958.
- Garnett WR. Acid-related disorders: Managing patient outcomes. *Pharm Times* 1995;6:61-70.
- Garnett WR. GI effects of OTC analgesics: Implications for product selection. *J Am Pharm Assoc* 1996;NS36:565-572.
- Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicenter, double-blind placebo-controlled trial. *Lancet* 1988;1277-1280.
- Graham DY, Go MF. *Helicobacter pylori*: Current status. *Gastroenterology* 1993;105:279-282.
- Graham DY, Klein PD, Opekun AR et al. Effect of age on the frequency of *Campylobacter pylori* infection diagnosed by the ¹³C-urea breath test on normal subjects and patients with peptic ulcer disease. *J Infect Dis* 1988;157:777-780.
- Graham DY, Lew GM, Klein PD, et al. Effect of treatment of *Helicobacter pylori* infection on the long-term recurrence of gastric or duodenal ulcer. *Ann Intern Med* 1992;116:705-708.
- Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of *Helicobacter pylori* with triple therapy. *Gastroenterology* 1992;102:493-496.
- Graham DY. *Helicobacter pylori* infection in the pathogenesis of duodenal ulcer and gastric ulcer and gastric cancer: A model. *Gastroenterology* 1997;113:1983-1991.
- Graham DY. *Helicobacter pylori*: Its epidemiology and its role in duodenal ulcer disease. *J Gastroenterol Hepatol* 1991;6:105-113.
- Greenberg PD, Koch J, Cello JP. Clinical utility and cost effectiveness of *Helicobacter pylori* testing for patients with duodenal and gastric ulcers. *Am J Gastroenterol* 1991;228-233.
- Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue steady state. *Antimicrob Agents Chemother* 1995;39:2078-2083.
- Harris AW, Misiewicz JJ. Eradication of *Helicobacter pylori*. *Baillieres Clin Gastroenterol* 1995;9:583-613.
- Holt PR. General perspectives on the aged gut. *Clin Geriatr Med* 1991;7:185-189.
- Hopkins RJ, Girardi LS, Turney EA. Relationship between *Helicobacter pylori* eradication and reduced duodenal and gastric ulcer recurrence: A review. *Gastroenterology* 1996;110:1244-1252.
- Hopkins RJ. Current FDA-approved treatments for *Helicobacter pylori* and the FDA approval process. *Gastroenterology* 1997;113(suppl):S126-S130.
- Hosking SW, Ling TK, Yung MY, et al. Randomized controlled trial of short term treatment to eradicate *Helicobacter pylori* in patients with duodenal ulcer. *Br Med J* 1992;305:502-504.
- Hudson N, Taha AS, Russesll RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. *Gastroenterology*. 1997;112:1817-1822.
- Hunt RH. pH and Hp -gastric acid secretion and *Helicobacter pylori*: implications for ulcer healing and eradication of the organism. *Am J Gastroenterol* 1993;88:481-483.
- Imperiale TF, Speroff T, Cebul RD, McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. *Ann Intern Med* 1995;123:665-672.
- International Agency for Research on Cancer. Schistosomes, liver flukes and *Helicobacter pylori*. IARC monographs on the evaluation of carcinogenic risks to humans. 1994;61:218-220.

... BIBLIOGRAPHY ...

- Jaspersen D, Koerner T, Schorr W, et al. *Helicobacter pylori* eradication reduces the rate of rebleeding in ulcer hemorrhage. *Gastrointest Endosc* 1995;41:5-7.
- Jensen DM Economic and health aspects of peptic ulcer disease and H₂-receptor antagonists. *Am J Med* 1986;81(suppl 4B):42-48.
- Jones DB, Howden CW, Vurget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. *Gut* 1987;28:1120-1127.
- Kimmey MB. Aspirin and nonaspirin NSAIDs in OTC doses: Clinical implications of their effects on the gastrointestinal mucosa. *Clinical Safety of OTC Analgesics*. Healthcare Information Programs, McGraw-Hill Companies, Inc; 1996, p 7-14.
- Kurata J, Nogawa A, Watanabe Y, Kawai K. Peptic ulcer disease mortality. Comparison of native Japanese, Japanese Americans, and Caucasian Americans. *J Clin Gastroenterol* 1994;18:145-154.
- Lahoi RJ, Jansen JBMJ, van de Lisdonk EH, Severons JL, Verbeek ALM. Symptom improvement through eradication of *Helicobacter pylori* in patients with nonulcer dyspepsia (review). *Aliment Pharmacol Ther* 1996;10:843-850.
- Laine L, Estrada R, Trujillo M, Fukunaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther* 1996;10:1029-1033.
- Laine L, Estrada R, Trujillo E, Fukunaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther* 1996;10:1029-1033.
- Laine L, Estrada R, Trujillo M, Emami S. Randomized comparison of ranitidine bismuth citrate (RBS)-based triple therapies for *H pylori* (*Hp*) (abstr). *Gastroenterology* 1997;112:A192.
- Laine L, Main-Sorensen M, Weinstein WM. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require *Helicobacter pylori* for their development. *Am J Gastroenterol* 1992;87:1389-1402.
- Lee A. *Helicobacter pylori*: The organism. In: Axon ATR, ed. *Helicobacter pylori. Its Role in Gastrointestinal Disease*. London, England: Science Press, 1994:1-10.
- Levitan R. GI problems in the elderly: Prevalent diseases and disorders. *Geriatrics* 1989;44:80-86.
- Lin SK, Lambert JR, Katz B, et al. High prevalence of *Helicobacter pylori* in practicing gastroenterologists (abstr). *Gastroenterology* 1991;100:A111.
- Loffeld RJLF, Stobberingh E, Arends JW. A review of diagnostic techniques for *Helicobacter pylori* infection. *Dig Dis Sci* 1993;11:173-180.
- Lorang F, Moun B, Haug JB, et al. Highly effective twice-daily triple therapies for *Helicobacter pylori* infection and peptic ulcer disease: Does in vitro metronidazole resistance have any clinical relevance? *Am J Gastroenterol* 1997;92:248-253.
- Malaty HM, Engstrand L, Pedersen NL, Graham DY. *Helicobacter pylori* infection: Genetic and environmental influences. *Ann Intern Med* 1994;120:982-986.
- Malaty HM, Graham DY, Klein PD, Evans DG, Adam E, Evans DJ. Transmission of *Helicobacter pylori* infection. *Scand J Gastroenterol* 1991;26:927-932.
- Malfertheiner P. Compliance, adverse events and antibiotic resistance in *Helicobacter pylori* treatment. *Scand J Gastroenterol* 1993;28(suppl 196):34-37.
- Marks IN, Wright JD, Gilinsky NH, et al. A comparison of sucralfate dosage schedules in duodenal ulcer healing. *J Clin Gastroenterol* 1986;8:419-423.
- Marshall BJ, Armstrong JA, McGeachie DB, Glancy RJ. Attempt to fulfill Koch's postulates for pyloric campylobacter. *Med J Aust* 1985;142:436-439.
- Marshall BJ. *Helicobacter pylori*. *Am J Gastroenterology* 1994;89:S116-S126.
- McColl KEL, El-Omar E. *Helicobacter pylori* and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. *Scand J Gastroenterol* 1996;31(Suppl 215):32-37.
- McFarland RJ, Bateson MC, Green JRB, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. *Gastroenterology* 1990;98:278-283.
- Megraud F. How should *Helicobacter pylori* be diagnosed? *Gastroenterology* 1997;113(suppl):S93-S98.
- Megraud F. Resistance of *Helicobacter pylori* to antibiotics. *Aliment Pharmacol Ther*. 1997;11(suppl 1):43-53.
- Miehke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxicillin improves the cure of *Helicobacter pylori* infection (abstr). *Gastroenterology* 1995;109:A167.
- Mobley HLT, Hu LT, Foxall PA. *Helicobacter pylori* urease: properties and role in pathogenesis. *Scand J Gastroenterol* 1991;187(suppl):39-46.
- Morreale AP. Pharmacist-managed *Helicobacter pylori* clinic. *Am J Health-Syst Pharm* 1995;52:183-185.

- Noach LA, Langberg WL, Bertola MA, et al. Impact of metronidazole resistance in the eradication of *Helicobacter pylori*. *Scand J Infect Dis* 1994;26:321-327.
- O'Brien B, Goereet R, Mohamed AH, Hunt R. Cost-effectiveness of *Helicobacter pylori* eradication for the long-term management of duodenal ulcer in Canada. *Arch Intern Med* 1995;155:1958-1964.
- Ofman JJ, Etchason JE, Fullerton S, Kahn KL, Soll AH. Management strategies for *Helicobacter pylori*-seropositive patients with dyspepsia: Clinical and economic consequences. *Ann Intern Med* 1997;126:280-291.
- Patchin GM, Wieland KA, Carmichael JM. Six months' experience with a pharmacist-run *Helicobacter* treatment clinic. *Am J Health-Syst Pharm* 1996;53:2061-2062.
- Permutt RP, Cello JP. Duodenal ulcer disease in the hospitalized elderly patient. *Dig Dis Sci* 1982;27:1-6.
- Phull PS, Pyder SD, Halliday D, et al. The economic and quality-of-life benefits of *Helicobacter pylori* eradication in chronic duodenal ulcer disease—A community-based study. *Postgrad Med J* 1995;71:413-418.
- Puller T, Birtwell AJ, Wiles PG, Hay A, Freely MD. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. *Clin Pharmacol Ther* 1988;44:540-545.
- Reilly TG, Ayers RC, Poxon V, Walt RP. *Helicobacter pylori* in a clinical setting: Success rates and the effect on the quality of life in peptic ulcer disease. *Aliment Pharmacol* 1995;9:483-490.
- Report of the Digestive Health Initiative International Update Conference on *Helicobacter pylori*. *Gastroenterology* 1997;113(Suppl):S4-S8.
- Roth SH. NSAID gastropathy. A new understanding. *Arch Intern Med* 1996;156:1623-1628.
- Sachs G, Shin JM, Besancon M, et al. The continuing development of gastric acid pump inhibitors. *Aliment Pharmacol Ther* 1993;7(suppl 1):4-12, 29-31.
- Saltiel E, Wright N. Development of a practice guideline for dyspepsia in a managed care environment. Presented at the Educational Conference of the Academy of Managed Care Pharmacists, Seattle, WA, October 31, 1997.
- Santander C, Gravalos RG, Gomez-Cedenilla A, et al. Antimicrobial therapy for *Helicobacter pylori* versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: A prospective randomized trial of 1225 patients. *Am J Gastroenterol* 1996;91:1549-1552.
- Scarignato C. Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa? *Dig Dis* 1995;13(suppl 1):9-39.
- Scheiman JM. NSAID-induced peptic ulcer disease: A critical review of pathogenesis and management. *Dig Dis* 1994;12:210-222.
- Schwartz H, Krause R, Sahba B, et al. Triple vs. dual therapy with lansoprazole, clarithromycin and/or amoxicillin in the eradication of *Helicobacter pylori* (abstr). *Am J Gastroenterol* 1996;90:2047.
- Segal R, Russell WL, Ben-Joseph R, Mansheim B. Cost of acid peptic disorders in a managed-care organization. *Clin Ther* 1996;18:319-333.
- Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1995;123:241-249.
- Singh G, Ramey Dr, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. *Arch Intern Med* 1996;156:1530-1536.
- Skander MP, Ryan FP. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. *Br Med J* 1988;297:833-834.
- Soll AH. Medical treatment of peptic ulcer disease: Practice guidelines *JAMA* 1996;275:622-629.
- Soll AH. Pathogenesis of peptic ulcer and implications for therapy. *N Engl J Med* 1990;322:909-916.
- Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. *Arch Intern Med* 1995;155:922-928.
- Sonnenberg A. Cost-benefit analysis of testing for *Helicobacter pylori* in dyspeptic subjects. *Am J Gastroenterol* 1996;91:1773-1777.
- Talley NJ. *Helicobacter pylori* and nonulcer dyspepsia. *Scand J Gastroenterol* 1996;31(Suppl 220):19-22.
- Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of *Helicobacter pylori*. *Arch Intern Med* 1997;157:87-97.
- Treiber G. The influence of drug dosage on *Helicobacter pylori* eradication: A cost-effectiveness analysis. *Am J Gastroenterol* 1996;91:246-257.
- Tytgat GNJ, Noach LA, Rauws EAJ. *Helicobacter pylori* infection and duodenal ulcer disease. *Gastroenterol Clin N Amer* 1993;22:127-139.

... BIBLIOGRAPHY ...

- Unge P. What other regimens are under investigation to treat *Helicobacter pylori*? *Gastroenterology* 1997;113 (Suppl):S131-S148.
- Vakil N, Fennerty B. Cost-effectiveness of *H pylori* eradication regimens: Efficacy vs effectiveness (abstr). *Gut* 1997;41(Suppl 1):A89.
- Vakil N, Fennerty M. Cost-effectiveness of treatment regimens for *H pylori* infection based on a community practice effectiveness study (abstr). *Gastroenterology* 1997;112:A47.
- Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of *Helicobacter pylori* in duodenal ulcer. *Am J Gastroenterol* 1996;91:239-245.
- Vane J. Towards a better aspirin. *Nature* 1994;367:215-216.
- Veldhuyzen van Zanten SJO, Pollak PT, Best LM, Bezanon GS, Marrie T. Increasing prevalence of *Helicobacter pylori* infection with age: Continuous risk of infection in adults rather than a cohort effect. *J Infect Dis* 1994;169:434-437.
- Veldhuzyen van Zanten A, Hunt RH, Cockeram A, et al. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for *Helicobacter pylori* gastritis: A randomized, double-blind trial showing the importance of metronidazole resistance. *Am J Gastroenterol* 1998;93:5-10.
- Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. *N Engl J Med* 1989;320:69-75.
- Walsh JH, Peterson WL. The treatment of *Helicobacter pylori* infection in the management of peptic ulcer disease. *N Engl J Med* 1995;333:984-991.
- Webb PM, Knight T, Greaves S, et al. Relation between infection with *Helicobacter pylori* and living conditions in childhood: evidence for person to person transmission in early life. *Br Med J* 1994;308:750-753.
- Weissfeld A, Haber M, Rose P, et al. Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with *Helicobacter pylori* (abstr). *Gastroenterology* 1997;112:A328.
- Wilhemsen I, Berstad A. Quality of life and relapse of duodenal ulcer before and after eradication of *Helicobacter pylori*. *Scand J Gastroenterol* 1994;29:874-879.
- Wilhoite SL, Ferguson DA, Soike DR, Kalbfleisch JH, Thomas E. Increased prevalence of *Helicobacter pylori* antibodies among nurses. *Arch Intern Med* 1993;153:708-712.